Holen Sie sich die Stockscreener-App
1.64
3.53%
-0.06
Schlusskurs vom Vortag:
$1.70
Offen:
$1.61
24-Stunden-Volumen:
127.97K
Relative Volume:
5.84
Marktkapitalisierung:
$76.73M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-13.68%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.58
$1.68
1-Wochen-Bereich:
$1.58
$1.925
52-Wochen-Spanne:
$1.58
$2.09
Whitehawk Therapeutics Inc Stock (WHWK) Company Profile
Firmenname
Whitehawk Therapeutics Inc
Sektor
Branche
Telefon
551-321-2234
Adresse
2 HEADQUARTERS PLAZA, MORRISTOWN
Vergleichen Sie WHWK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
WHWK
Whitehawk Therapeutics Inc
|
1.64 | 76.73M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Whitehawk Therapeutics Inc Stock (WHWK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-27 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-08-21 | Herabstufung | Jefferies | Buy → Hold |
| 2024-08-21 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-01-11 | Eingeleitet | Jefferies | Buy |
| 2021-10-01 | Eingeleitet | Cowen | Outperform |
| 2021-09-14 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-09-08 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Whitehawk Therapeutics Inc Aktie (WHWK) Neueste Nachrichten
Whitehawk Therapeutics - The Pharma Letter
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations - MarketScreener
Aadi Bioscience to Participate at Upcoming Investor Conferences - MarketScreener
Aadi Bioscience to Participate in Upcoming Investor Events - MarketScreener
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - MarketScreener
Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting - MarketScreener
Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference - MarketScreener
Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes - MarketScreener
Whitehawk Therapeutics, Inc. SEC 10-K Report - TradingView
Kaken Pharmaceutical Co., Ltd. entered into a stock purchase agreement to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. for $100 million. - MarketScreener
Whitehawk Therapeutics Closes Sale of Aadi Subsidiary to Kaken Pharmaceuticals - citybiz
Whitehawk Therapeutics sells subsidiary for $102.4 million By Investing.com - Investing.com South Africa
Whitehawk Therapeutics sells subsidiary for $102.4 million - Investing.com
Whitehawk sells Aadi Subsidiary to Kaken for $100 million - Investing.com
Whitehawk sells Aadi Subsidiary to Kaken for $100 million By Investing.com - Investing.com UK
Whitehawk Therapeutics Completes Strategic Transformation With Successful Closing Of Sale Of Aadi Subsidiary To Kaken Pharmaceuticals - Marketscreener.com
Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals - The Victoria Advocate
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing - MarketScreener
Aadi Bioscience Announces Participation in Upcoming September Investor Conferences - MarketScreener
Aadi Bioscience Announces Leadership Transition - MarketScreener
Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium - MarketScreener
Aadi Bioscience, Inc. (NASDAQ:AADI) Q4 2024 Earnings Call Transcript - Insider Monkey
Aadi Bioscience’s Earnings Call: Strategic Shifts and Promising Pipeline - TipRanks
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update - Marketscreener.com
Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update - MarketScreener
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update - Marketscreener.com
Aadi Bioscience, Inc. Announces CEO Changes - MarketScreener
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) - Marketscreener.com
Aadi Bioscience to Participate in the Jefferies Healthcare Conference - MarketScreener
Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer - MarketScreener
Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders - Marketscreener.com
Aadi Bioscience Inc (AADI) Q4 2024 Earnings Call Highlights: Strategic Transition and Financial ... By GuruFocus - Investing.com Canada
Whitehawk Therapeutics: Strategic Shift and Financial Outlook - TipRanks
Aadi rebrands as Whitehawk Therapeutics in new ADC focus - The Pharma Letter
Novartis cuts over 400 jobs ahead of Entresto patent loss - The Pharma Letter
Six new option listings and four option delistings on March 19th - TipRanks
Aadi Bioscience, Inc. will Change its Name to Whitehawk Therapeutics, Inc -March 19, 2025 at 12:00 am EDT - Marketscreener.com
Aadi Bioscience Inc changes name to Whitehawk Therapeutics -March 18, 2025 at 05:58 pm EDT - Marketscreener.com
Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company - Longview News-Journal
Major Transformation: Aadi Becomes Whitehawk with $180M War Chest for ADC Cancer Programs - Stock Titan
Aadi Bioscience Announces Closing of $100 Million PIPE Financing - MarketScreener
WhiteHawk Capital Partners Provides Credit Facility to Nephron Pharmaceuticals - Business Wire
Finance Watch: Generation Bio, CytomX Right-Size Operations Ahead Of J.P. Morgan - News & Insights
PHX Minerals Explores Sale After Rejecting Acquisition Bids - Yahoo Finance
Aadi Bioscience downgraded to Neutral, shares fall (NASDAQ:AADI) - Seeking Alpha
Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates - MarketScreener
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update - MarketScreener
Closing Bell: We’ve got a WhiteHawk up as tech takes over ASX200 - Stockhead
Alnylam takes 10% hit on Amvuttra trial tinkering - The Pharma Letter
Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update - MarketScreener
Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer - MarketScreener
Finanzdaten der Whitehawk Therapeutics Inc-Aktie (WHWK)
Es liegen keine Finanzdaten für Whitehawk Therapeutics Inc (WHWK) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):